Wedbush Research Analysts Raise Earnings Estimates for Geron

Geron Co. (NASDAQ:GERN) – Wedbush raised their Q2 2025 EPS estimates for Geron in a report issued on Wednesday, February 26th. Wedbush analyst R. Driscoll now expects that the biopharmaceutical company will post earnings per share of ($0.03) for the quarter, up from their prior estimate of ($0.04). The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Wedbush also issued estimates for Geron’s Q3 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.14) EPS, FY2027 earnings at $0.43 EPS and FY2028 earnings at $0.84 EPS.

Geron (NASDAQ:GERN) last announced its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.04). Geron had a negative net margin of 682.48% and a negative return on equity of 67.53%. The firm had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million.

Several other research analysts have also issued reports on the stock. Stifel Nicolaus lowered their price target on shares of Geron from $8.00 to $4.00 and set a “buy” rating for the company in a report on Thursday, February 27th. Needham & Company LLC reduced their price target on shares of Geron from $7.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, February 27th. Barclays reaffirmed an “overweight” rating and set a $4.00 price objective (down from $9.00) on shares of Geron in a report on Thursday, February 27th. HC Wainwright downgraded shares of Geron from a “buy” rating to a “neutral” rating in a report on Wednesday, February 26th. Finally, B. Riley downgraded shares of Geron from a “buy” rating to a “neutral” rating and cut their price target for the stock from $3.50 to $2.00 in a report on Thursday, February 27th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Geron presently has a consensus rating of “Moderate Buy” and a consensus target price of $5.68.

Geron Stock Down 2.9 %

NASDAQ:GERN opened at $1.66 on Monday. The firm’s 50 day simple moving average is $2.90 and its 200 day simple moving average is $3.75. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.89 and a quick ratio of 2.74. Geron has a one year low of $1.46 and a one year high of $5.34. The company has a market cap of $1.00 billion, a PE ratio of -5.19 and a beta of 0.53.

Institutional Investors Weigh In On Geron

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GERN. RTW Investments LP purchased a new position in shares of Geron in the third quarter worth about $200,268,000. Vanguard Group Inc. boosted its stake in shares of Geron by 3.4% in the fourth quarter. Vanguard Group Inc. now owns 33,538,822 shares of the biopharmaceutical company’s stock worth $118,727,000 after acquiring an additional 1,088,912 shares during the last quarter. State Street Corp boosted its stake in shares of Geron by 28.4% in the third quarter. State Street Corp now owns 28,961,671 shares of the biopharmaceutical company’s stock worth $131,486,000 after acquiring an additional 6,413,204 shares during the last quarter. Janus Henderson Group PLC lifted its position in Geron by 20.0% during the fourth quarter. Janus Henderson Group PLC now owns 27,082,461 shares of the biopharmaceutical company’s stock worth $95,769,000 after buying an additional 4,516,615 shares in the last quarter. Finally, Holocene Advisors LP purchased a new position in Geron during the third quarter worth approximately $82,498,000. 73.71% of the stock is currently owned by hedge funds and other institutional investors.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.